BiVictriX Therapeutics PLC 12 August 2024 This announcement contains inside information for the purposes of Article 7 of Regulation (EU) No 596/2014 as it forms part of UK domestic law by virtue of the European Union (Withdrawal) Act 2018. With the publication of this announcement via a Regulatory Information Service, this inside information is now […]
Copyright © 2023 JP Jenkins. All rights reserved. JP Jenkins is a trading name of Infinitx Limited a company incorporated in England & Wales with registered number 11551708 and whose registered office is at 101 Wigmore Street, 5th Floor, London, England, W1U 1QU (JPJ). JPJ (FRN 950991) is an appointed representative of Prosper Capital LLP (FRN453007) (Prosper) which is authorised and regulated by the Financial Conduct Authority. This website is a financial promotion by JPJ. It is not intended to be a promotion of any individual investment opportunity and is not an offer to the public. JPJ acts for the companies listed on the website and provides services to authorised brokers but does not act for investors, consumers or any other person. The information on this website is obtained from the companies and other third parties and although JPJ considers these sources to be reliable, it makes no representation as to the accuracy of the information. Neither JPJ, Prosper nor any member of their group provides any advice on investing in unlisted shares generally or in the companies listed on the platform specifically, nor any legal, financial or tax advice of any kind. Nothing on this website and no communication from JPJ should be construed as an investment recommendation. If you have any doubt about the suitability of the investment, or you require financial advice, you should seek a personal recommendation from an appropriately qualified financial advisor. Investing in unlisted shares is high risk and should only be done as part of a diversified portfolio. Please read the RISK WARNINGS before making any investment decisions. Offers are only available through authorised persons. Any person resident outside the United Kingdom should ensure that they are not subject to any local regulations before investing. Nothing on this website constitutes an offer to sell, or a solicitation of an offer to buy, any security to any person in any jurisdiction to whom or in which such offer, solicitation or sale is unlawful. If you have any questions regarding these matters relating to information on this website you should consult a professional adviser.
Trading Instructions:
To buy and sell shares in this company via JP Jenkins, you will need to use a regulated UK stockbroker.
For a comprehensive list of brokers click here.
Over 40 UK brokers regularly connect with our platform.
If you are based overseas and are interested in participating then please contact us directly by emailing info@jpjenkins.com or by calling 0207 469 0937
Trades take place through our central counterparty partner. There is a fee of 1.5% of the transaction price which is charged to both buyers and sellers and a £25 transaction fee. Your broker may also apply charges.
Please note, when purchasing shares Stamp Duty Reserve Tax (“SDRT”) may be applicable.
